NCT06591806Active, not recruiting
An Observational Study in Children and Adults With Stargardt Disease
A Multicenter, Prospective, Longitudinal, Observational Study in Children and Adults With Stargardt Disease Related Atrophy Secondary to Biallelic Mutations in the ABCA4 Gene
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
This multicenter, prospective, longitudinal, observational study in approximately 80 subjects with Stargardt disease secondary to biallelic mutations in the ABCA4 gene (STGD1) aims to evaluate prognostic factors of disease progression, and to further characterize the patient population for future clinical studies.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 29 Jul 2024
- Start date
- 1 May 2024
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- AAVantgarde Bio Srl
- NCT number
- NCT06591806
What you commit to
- Study type: Observational
- Planned participants: 80
- From 1 May 2024 to the primary completion date, 30 Jun 2027
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of uveitis.
- Any ocular disease in either eye that may confound assessment of the retina morphologically and functionally.
Other
- Any pathology of the posterior segment other than ABCA4 retinopathy.
- Presence of any other genetic mutation(s) that have been associated with retinal or macular dystrophy.
Who the study is looking for
- Male and female subjects between 8 and 50 years of age at the time of enrolment.
- Willingness to adhere to the protocol as evidenced by written informed consent if the subject is 18 years or older. If the subject is under 18 years of age, written assent must be obtained from the subject and written informed consent must be obtained from the subject's legally authorized representative (parent or legal guardian).
- Confirmed mutation in the ABCA4 gene.
Age in the registry: 8 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hospital Ullevål Coordinator of this site? Confirm its status | Oslo | Norway | Unknown status |
| Retina Foundation of the Southwest Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.